3sbio competitorsClear all
3sbio's top competitors include BioNTech, TOT BIOPHARM, Iovance Biotherapeutics and Oncopeptides.
 BioNTech BioNTech is biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. |  Iovance Biotherapeutics Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes. | ||||
Founding Date | Founding Date 1993 | Founding Date 2008 | Founding Date 2009 | Founding Date 2013 | Founding Date 2000 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations George Town, KY HQ | Locations Mainz, DE HQ Halle (Saale), DE Idar Oberstein, DE Marburg, DE Neuried, DE Planegg, DE Cambridge, US see more | Locations Suzhou Shi, CN HQ | Locations San Carlos, US HQ New York, US Philadelphia, US Philadelphia, US Tampa, US | Locations Stockholm, SE HQ Stockholm, SE Los Altos, US Mountain View, US Waltham, US |
Employees | Employees 5,2325% decrease | Employees 1,94149% increase | Employees 3375% decrease | Employees 14868% increase | Employees 16250% decrease |
Alexa Website Rank | Alexa Website Rank 302555 | Alexa Website Rank 137148 | Alexa Website Rank 563566 | Alexa Website Rank 674367 | Alexa Website Rank 765507 |
Employee Rating | Employee Rating 3 | Employee Rating 3.3 | Employee Rating N/A | Employee Rating 3.1 | Employee Rating 4.3 |
Financial | |||||
Revenue (est.) | Revenue (est.) ¥6.4b (FY, 2021) | Revenue (est.) €19b (FY, 2021) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) kr118.3m (FY, 2021) |
Cost of goods | Cost of goods (¥777.3m) (FY, 2021) | Cost of goods (€2.9b) (FY, 2021) | Cost of goods N/A | Cost of goods N/A | Cost of goods (kr53.1m) (FY, 2021) |
Gross profit | Gross profit ¥5.7b (FY, 2021) | Gross profit €16.2b (FY, 2021) | Gross profit N/A | Gross profit N/A | Gross profit kr132.8m (FY, 2021) |
Net income | Net income ¥1.6b (FY, 2021) | Net income €10.3b (FY, 2021) | Net income N/A | Net income ($259.6m) (FY, 2020) | Net income (kr1.4b) (FY, 2021) |
Funding | |||||
Total funding raised | Total funding raised $ 15.2m | Total funding raised $ 1.4b | Total funding raised $ 108m | Total funding raised $ 100m | Total funding raised N/A |
For sources of this data, please see the company profile
View company profiles
BioNTech
HQ
Mainz, DE
Employees
1,941↑ 49% increase
BioNTech is biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.
View company
TOT BIOPHARM
HQ
Suzhou Shi, CN
Employees
337↓ 5% decrease
TOT BIOPHARM is a biopharmaceutical company that develops oncology drugs and therapies.
View companyIovance Biotherapeutics
HQ
San Carlos, US
Employees
148
Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes.
View company
Oncopeptides
HQ
Stockholm, SE
Employees
162↓ 50% decrease
Oncopeptides is a clinical development pharmaceutical company.
View company